Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself ...

US biotech ImmunityBio (Nasdaq: IBRX) has secured $75 million through a direct offering with a single institutional investor, according to a statement released Tuesday. The deal involved the sale of ...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing organizations ...

Ethris reported initial positive Phase I data for its intranasal mRNA vaccine candidate, ETH47. "Ethris and Lonza to develop mRNA vaccines for respiratory conditions ...

Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory conditions.

Proposed cuts to USAID are being felt throughout the world. Credit: via Shutterstock. The clinical supply chain in Africa is striving to manage the impact of the US decision to withdraw from the World ...

MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest ...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world's largest contract development and manufacturing organizations ...

Under the terms of the agreement, Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized ...

Formulations to be developed at Lonza’s Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US), in accordance with current Good Manufacturing Practice (cGMP) standards ...